Evidence map›Paper›PMID 35355539›Full record

ArticleCureus2022

Neurotoxicity: A Rare Side Effect of Programmed Cell Death 1 (PD-1) Inhibitors.

Syed Ehsanullah, Syed Hasan, Faran S Polani, Syeda Zarmeena Rashid, Syed Ijlal Ahmed

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Syed EhsanullahMedicine, Washington University School of Medicine, St. Louis, USA.
Syed HasanOncology, Washington University School of Medicine, St. Louis, USA.
Faran S PolaniInternal Medicine, Washington University School of Medicine, St. Louis, USA.
Syeda Zarmeena RashidInternal Medicine, Dow University of Health Sciences, Dow International Medical College, Karachi, PAK.
Syed Ijlal AhmedNeurology, Saint Louis University School of Medicine, St. Louis, USA.
Washington University in St. Louis · USDow University of Health Sciences · PKSaint Louis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is a biological therapy that helps the body's immune system to fight against cancer cells. The Food and Drug Administration (FDA) approved the first immune checkpoint inhibitor in 2011. Since 2011, many immune checkpoint inhibitors have been approved. Programmed cell death 1 (PD-1) inhibitors are now commonly used in multiple malignancies due to their remarkable response. Thus, immune-related adverse events are now coming into the limelight due to the increasing use of PD-1 inhibitors. Here, we present a case of a 54-year-old female with non-small cell lung cancers (NSCLC) treated with pembrolizumab and later presented with severe neurotoxicity.

Indexed as

anti-pd-1immuno-checkpoint inhibitorimmunotherapy adverse effectlung cancernon-small cell lung cancer (nsclc)

Identifiers

PMID35355539
PMCPMC8957660
OpenAlexW4214628103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.